Kotak Invests in Cellogen Therapeutics
x
Kotak Asset Managers invests Rs 20 cr in Cellogen Therapeutics. Funds to advance CAR'T clinical programs and expand gene therapy pipeline.
Mumbai, May 18 (PTI) Kotak Alternate Asset Managers on Monday said it has invested Rs 20 crore in NATCO Pharma-backed Cellogen Therapeutics.
The investment has been made through Kotak Life Sciences Fund I (KLSF-I), which typically invests in early- to growth-stage life sciences and healthcare businesses. Cellogen will use the funds to advance its CAR'T clinical programmes, expand its gene therapy pipeline, and strengthen manufacturing, a release said.
****
*Damroo raises Rs 5 crore from Hindustan Times
Music streaming platform Damroo on Monday announced a Rs 5 crore fund raise from Hindustan Times.
The funding will support the platform's efforts to scale artist development, audience growth, monetisation, and industry support initiatives, according to a statement.
The investment has been made through Kotak Life Sciences Fund I (KLSF-I), which typically invests in early- to growth-stage life sciences and healthcare businesses. Cellogen will use the funds to advance its CAR'T clinical programmes, expand its gene therapy pipeline, and strengthen manufacturing, a release said.
****
*Damroo raises Rs 5 crore from Hindustan Times
Music streaming platform Damroo on Monday announced a Rs 5 crore fund raise from Hindustan Times.
The funding will support the platform's efforts to scale artist development, audience growth, monetisation, and industry support initiatives, according to a statement.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone-Idea
- 14.90 (+ 5.08)
- 69449321
- Standard-Cap-Mkt
- 0.39 (+ 5.41)
- 37491612
- Evexia-Lifecare
- 1.75 (+ 2.94)
- 34325250
- IFCI
- 84.63 (+ 19.99)
- 23166160
- Sylph-Industries
- 0.29 ( -3.33)
- 16563257






